Evolent Health's Q2 Net Loss Widens to $26.3M Amid Revenue Surge

TL;DR

EVH's revenue growth is impressive, but the ballooning net loss means they're burning cash, making it a risky bet right now.

AI Summary

Evolent Health, Inc. (EVH) reported a net loss of $26.3 million for the three months ended June 30, 2025, a significant increase from the $2.9 million net loss in the prior-year period. Revenue for the second quarter of 2025 reached $556.2 million, up from $299.1 million in the second quarter of 2024, representing an 86% increase. The company's selling, general, and administrative expenses also rose substantially to $105.7 million for the three months ended June 30, 2025, compared to $65.4 million for the same period in 2024. This increase in expenses, alongside a $2.6 million change in contingent consideration arrangements, contributed to the expanded net loss. Evolent Health continues to focus on its value-based care solutions, but the increased operational costs and contingent liabilities are impacting profitability. The strategic outlook remains centered on expanding its platform, though the current financial results highlight challenges in scaling operations efficiently.

Why It Matters

Evolent Health's widening net loss, despite robust revenue growth, signals potential challenges in managing operational costs and integrating acquisitions, which could concern investors. For employees, sustained losses might impact future growth opportunities or compensation. Customers could benefit from the company's expanding platform, but financial instability could raise questions about long-term service reliability. In the competitive healthcare technology market, Evolent's ability to translate revenue into profit is crucial for maintaining its market position against rivals like Optum and Cerner.

Risk Assessment

Risk Level: high — The risk level is high due to the significant increase in net loss to $26.3 million in Q2 2025 from $2.9 million in Q2 2024, despite an 86% revenue increase. This indicates a struggle with profitability and cost control, with selling, general, and administrative expenses rising to $105.7 million.

Analyst Insight

Investors should exercise caution and closely monitor Evolent Health's next earnings reports for signs of improved cost management and a path to profitability. Consider holding off on new investments until there's clear evidence the company can convert its strong revenue growth into sustainable net income.

Financial Highlights

revenue

$556.2M

net Income

-$26.3M

revenue Growth

+86%

Key Numbers

• $26.3M — Net Loss (Increased from $2.9M in Q2 2024, indicating worsening profitability.)
• $556.2M — Revenue (Up 86% from $299.1M in Q2 2024, showing strong top-line growth.)
• $105.7M — SG&A Expenses (Increased from $65.4M in Q2 2024, contributing to wider net loss.)
• 86% — Revenue Growth (Year-over-year increase in Q2 2025 revenue, demonstrating market expansion.)
• $2.6M — Contingent Consideration Change (Additional liability impacting net loss in Q2 2025.)

Key Players & Entities

• Evolent Health, Inc. (company) — filer of the 10-Q
• $26.3 million (dollar_amount) — net loss for Q2 2025
• $2.9 million (dollar_amount) — net loss for Q2 2024
• $556.2 million (dollar_amount) — revenue for Q2 2025
• $299.1 million (dollar_amount) — revenue for Q2 2024
• $105.7 million (dollar_amount) — selling, general, and administrative expenses for Q2 2025
• $65.4 million (dollar_amount) — selling, general, and administrative expenses for Q2 2024
• $2.6 million (dollar_amount) — change in contingent consideration arrangements
• Optum (company) — competitor in healthcare technology market
• Cerner (company) — competitor in healthcare technology market

FAQ

Risk Factors

• Increased Net Loss and Operating Expenses [high — financial]: Evolent Health reported a net loss of $26.3 million for Q2 2025, a significant deterioration from the $2.9 million net loss in Q2 2024. This widening loss is attributed to a substantial increase in Selling, General, and Administrative (SG&A) expenses, which rose to $105.7 million from $65.4 million year-over-year. The company also experienced a $2.6 million change in contingent consideration arrangements, further impacting profitability.
• Challenges in Scaling Operations Efficiently [medium — operational]: Despite strong revenue growth of 86% to $556.2 million in Q2 2025, the company's profitability is being negatively affected by increased operational costs. The substantial rise in SG&A expenses suggests potential inefficiencies in scaling the business to support the rapid revenue expansion. This indicates a challenge in translating top-line growth into bottom-line improvement.
• Contingent Consideration Liabilities [medium — financial]: A $2.6 million change in contingent consideration arrangements contributed to the net loss in Q2 2025. These arrangements, often tied to acquisitions or performance milestones, can introduce volatility and unexpected financial obligations, making future earnings less predictable.

Industry Context

Evolent Health operates in the rapidly evolving healthcare technology and services sector, focusing on value-based care solutions. This industry is characterized by intense competition, increasing regulatory scrutiny, and a strong push towards digital transformation and data analytics to improve patient outcomes and reduce costs. Companies like Evolent are challenged to innovate and scale their platforms while navigating complex payer and provider relationships.

Regulatory Implications

The healthcare industry is subject to extensive regulation, including data privacy laws (like HIPAA) and evolving reimbursement policies. Changes in these regulations can significantly impact Evolent Health's business model and financial performance. Compliance costs and the need to adapt to new regulatory frameworks are ongoing considerations.

What Investors Should Do

1. Monitor SG&A expense trends closely.
2. Analyze the drivers of revenue growth.
3. Assess the impact of contingent liabilities.

Glossary

Contingent Consideration Arrangements

These are obligations to transfer additional assets or equity interests to an acquiree as part of a business combination. The amount of consideration can depend on future events or performance, such as achieving certain financial targets. (A $2.6 million change in these arrangements negatively impacted Evolent Health's net loss in Q2 2025, highlighting potential financial volatility and the cost of growth strategies.)

Selling, General, and Administrative Expenses (SG&A)

These are the costs incurred by a company that are not directly related to the production or acquisition of goods or services. They include expenses like marketing, salaries for administrative staff, and office rent. (The significant increase in SG&A expenses to $105.7 million in Q2 2025 from $65.4 million in Q2 2024 is a key driver of the widened net loss, indicating rising operational costs.)

Year-Over-Year Comparison

Compared to the prior year's second quarter, Evolent Health has demonstrated impressive revenue growth, increasing by 86% to $556.2 million. However, this top-line expansion has been overshadowed by a significant increase in operating expenses, particularly SG&A, which rose from $65.4 million to $105.7 million. This surge in costs has led to a substantial widening of the net loss, from $2.9 million to $26.3 million, indicating a deterioration in profitability despite strong market penetration.

Key Financial Figures

• $0.01 — tock of Evolent Health, Inc., par value $0.01 per share EVH New York Stock Exchange

Filing Documents

• evh-20250630.htm (10-Q) — 1698KB
• a6302025exhibit31.htm (EX-3.1) — 8KB
• a6302025exhibit101.htm (EX-10.1) — 188KB
• a6302025exhibit102.htm (EX-10.2) — 1331KB
• a6302025exhibit103.htm (EX-10.3) — 1225KB
• a6302025exhibit104.htm (EX-10.4) — 208KB
• a6302025exhibit105.htm (EX-10.5) — 96KB
• a6302025exhibit106.htm (EX-10.6) — 438KB
• a6302025exhibit107.htm (EX-10.7) — 1635KB
• a6302025exhibit311.htm (EX-31.1) — 11KB
• a6302025exhibit312.htm (EX-31.2) — 11KB
• a6302025exhibit321.htm (EX-32.1) — 5KB
• a6302025exhibit322.htm (EX-32.2) — 5KB
• 0001628908-25-000116.txt ( ) — 16221KB
• evh-20250630.xsd (EX-101.SCH) — 79KB
• evh-20250630_cal.xml (EX-101.CAL) — 95KB
• evh-20250630_def.xml (EX-101.DEF) — 320KB
• evh-20250630_lab.xml (EX-101.LAB) — 851KB
• evh-20250630_pre.xml (EX-101.PRE) — 614KB
• evh-20250630_htm.xml (XML) — 1616KB

Financial Statements

Financial Statements 1 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 37 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 49 4.

Controls and Procedures

Controls and Procedures 49 PART II 1.

Legal Proceedings

Legal Proceedings 51 1A.

Risk Factors

Risk Factors 51 2. Unregistered Sales of Equity Securities and Use of Proceeds 53 3. Defaults Upon Senior Securities 53 4. Mine Safety Disclosures 54 5. Other Information 54 6. Exhibits 55

Signatures

Signatures 57 Explanatory Note In this Quarterly Report on Form 10-Q, unless the context otherwise requires, "Evolent," the "Company," "we," "our" and "us" refer to Evolent Health, Inc. and its consolidated subsidiaries. Evolent Health LLC, a subsidiary of Evolent Health, Inc. through which we conduct our operations, has owned all of our operating assets and substantially all of our business since inception. Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units of Evolent Health LLC.

FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE

FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE Certain statements made in this report and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: "believe," "anticipate," "expect," "estimate," "aim," "predict," "potential," "continue," "plan," "project," "will," "should," "shall," "may," "might" and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to weather current dynamics, continue to expand our footprint, future actions, trends in our businesses, prospective services, new partner additions/expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA. These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements. Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others: the significant portion of revenue we derive from our largest partners, and the potential loss, termination or renegotiation of our relationship or contract with any significant partner, or multiple

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements EVOLENT HEALTH, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share data) June 30, 2025 December 31, 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 150,995 $ 104,203 Restricted cash 24,368 59,295 Accounts receivable, net (1) 358,756 414,681 Prepaid expenses and other current assets 28,138 28,938 Total current assets 562,257 607,117 Restricted cash 2,607 14,998 Investments and equity method investees 8,978 8,588 Property and equipment, net 77,273 73,151 Right-of-use assets - operating 5,342 6,134 Prepaid expenses and other noncurrent assets 4,081 3,569 Contract cost assets 12,504 13,378 Intangible assets, net 651,169 680,156 Goodwill 1,137,321 1,137,320 Total assets $ 2,461,532 $ 2,544,411 LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY Liabilities Current liabilities: Accounts payable (1) $ 69,460 $ 96,025 Accrued liabilities 63,886 66,361 Operating lease liability - current 24,208 26,717 Accrued compensation and employee benefits 38,262 33,719 Deferred revenue 2,333 2,507 Short-term debt, net 172,119 171,467 Reserve for claims and performance - based arrangements 187,251 318,705 Total current liabilities 557,519 715,501 Long-term debt, net 648,455 490,520 Other long-term liabilities 3,787 2,984 Tax receivables agreement liability 108,105 108,105 Operating lease liabilities - noncurrent 8,411 24,969 Deferred tax liabilities, net 10,450 10,900 Total liabilities 1,336,727 1,352,979 Commitments and Contingencies (See Note 10) Mezzanine Equity Preferred class A common stock - $ 0.01 par value; 50,000,000 shares authorized; 175,000 issued, respectively 228,800 190,173 Shareholders' Equity Class A common stock - $ 0.01 par value; 750,000,000 shares authorized; 117,472,681 and 116,575,773 shares issued, respectively 1,175 1,166 Additional paid-in-capital 1,782,992 1,803,786 Accumulated other comprehensive loss ( 1,707 ) ( 1,753 ) Retained earnings (accumul

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Note 1. Organization Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries is a market leader in connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. We work on behalf of health plans and other risk-bearing entities and payers (our customers) to support physicians and other healthcare providers (our users) in providing the best evidence-based care to their patients. We believe adherence to the best evidence supports better outcomes for patients, a better experience for physicians, and lower costs for the healthcare system overall. As of June 30, 2025, the Company had unrestricted cash and cash equivalents of $ 151.0 million. The Company believes it has sufficient liquidity to meet its working capital and capital expenditure requirements for at least the next twelve months as of the date the financial statements were issued. We have one operating segment and one reportable segment as our chief operating decision maker ("CODM"), who is our Chief Executive Officer, reviews financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. The Company's headquarters is located in Arlington, Virginia. Evolent Health LLC Governance Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC's business and affairs and is responsible for the management of its business. Note 2. Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles Basis of Presentation In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly stat

View Full Filing

View this 10-Q filing on SEC EDGAR